[go: up one dir, main page]

MX2012003082A - Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol. - Google Patents

Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.

Info

Publication number
MX2012003082A
MX2012003082A MX2012003082A MX2012003082A MX2012003082A MX 2012003082 A MX2012003082 A MX 2012003082A MX 2012003082 A MX2012003082 A MX 2012003082A MX 2012003082 A MX2012003082 A MX 2012003082A MX 2012003082 A MX2012003082 A MX 2012003082A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
dose dumping
induced dose
reducing alcohol
alcohol
Prior art date
Application number
MX2012003082A
Other languages
English (en)
Inventor
Sunilendu Bhushan Roy
Sushrut Krishnaji Kulkarni
Maulik Kiritkumar Panchal
Kartik Yogeshkumar Shah
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2012003082A publication Critical patent/MX2012003082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una composición farmacéutica. La composición comprende un núcleo que comprende una sustancia activa o una sal de la misma; una capa de separación que comprende al menos un azúcar y una capa funcional que comprende al menos un polímero farmacéuticamente aceptable, en donde la composición es resistente a la absorción rápida de la dosis en la presencia de alcohol.
MX2012003082A 2009-09-17 2010-09-09 Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol. MX2012003082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2154MU2009 2009-09-17
PCT/IN2010/000604 WO2011039768A2 (en) 2009-09-17 2010-09-09 Pharmaceutical compositions for reducing alcohol-induced dose dumping

Publications (1)

Publication Number Publication Date
MX2012003082A true MX2012003082A (es) 2012-04-19

Family

ID=43618126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003082A MX2012003082A (es) 2009-09-17 2010-09-09 Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.

Country Status (5)

Country Link
US (1) US20120207825A1 (es)
EP (1) EP2477614A2 (es)
JP (1) JP2013504562A (es)
MX (1) MX2012003082A (es)
WO (1) WO2011039768A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
HUE042593T2 (hu) * 2010-03-09 2019-07-29 Alkermes Pharma Ireland Ltd Alkoholnak ellenálló enterális gyógyszerkészítmények
KR20140053307A (ko) 2011-08-12 2014-05-07 베링거잉겔하임베트메디카게엠베하 맛이 차폐된 약제학적 조성물
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CN102920691A (zh) * 2012-10-23 2013-02-13 中美天津史克制药有限公司 含有布洛芬和伪麻黄碱的复方缓释胶囊
WO2014068586A2 (en) * 2012-10-31 2014-05-08 Hetero Research Foundation Solid oral compositions of tolvaptan
RU2018141241A (ru) 2012-11-30 2019-01-24 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
CN103127023B (zh) * 2013-03-01 2014-08-27 河北天成药业股份有限公司 一种盐酸度洛西汀肠溶片及其制备方法
WO2014151797A1 (en) * 2013-03-15 2014-09-25 Mylan, Inc. Extended release formulations resistant to alcohol dose dumping
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
CN103690506B (zh) * 2013-11-08 2015-05-13 舒泰神（北京）生物制药股份有限公司 一种曲司氯铵缓释组合物及其制备方法
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN104367582A (zh) * 2014-05-20 2015-02-25 南京海纳医药科技有限公司 一种含有硫酸氢氯吡格雷与阿司匹林活性成份的片剂及其制备方法
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017048566A1 (en) * 2015-09-15 2017-03-23 C.B. Fleet Company, Incorporated Bisacodyl compositions and delivery apparatus
US20180318246A1 (en) * 2015-10-28 2018-11-08 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6815109B2 (ja) * 2016-06-23 2021-01-20 キョーリンリメディオ株式会社 デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物
JP6972674B2 (ja) * 2017-06-06 2021-11-24 ニプロ株式会社 経口医薬製剤
CN107233328A (zh) * 2017-06-13 2017-10-10 江苏黄河药业股份有限公司 卡托普利缓释片剂及其制备方法
AU2018343214B2 (en) * 2017-09-29 2023-10-05 Kenvue Brands Llc Solid simethicone particles and dosage form thereof
CN109662948B (zh) * 2017-10-13 2021-04-16 上海上药信谊药厂有限公司 一种血小板凝集抑制剂及其制备方法
CA3085348A1 (en) 2017-12-20 2019-06-27 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
CN110327295A (zh) * 2019-08-05 2019-10-15 五邑大学 一种盐酸雷尼替丁缓释混悬液的配方及其制备方法
CN112569197A (zh) * 2020-12-25 2021-03-30 山东达因海洋生物制药股份有限公司 一种维生素d3组合物及其制备方法和应用
WO2024127365A1 (en) * 2022-12-17 2024-06-20 Sun Pharmaceutical Industries Limited Stable pharmaceutical composition of an amine drug
WO2025208003A1 (en) * 2024-03-29 2025-10-02 Sen-Jam Pharmaceutical Inc. Pharmaceutical formulations and manufacturing processes
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
TW200602089A (en) * 2004-06-07 2006-01-16 Wyeth Corp Sugar coatings and methods therefor
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060193912A1 (en) 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
EP1904039A2 (en) * 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
AU2006275476A1 (en) 2005-08-01 2007-02-08 Alpharma Inc. Alcohol resistant pharmaceutical formulations
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
US20080085304A1 (en) 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
CA2930487A1 (en) 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
MX2010008861A (es) * 2008-02-15 2011-02-22 Sun Pharma Advanced Res Co Ltd Tableta oral de liberacion controlada con efecto de liberacion masiva reducido.

Also Published As

Publication number Publication date
JP2013504562A (ja) 2013-02-07
EP2477614A2 (en) 2012-07-25
WO2011039768A2 (en) 2011-04-07
WO2011039768A3 (en) 2011-09-01
US20120207825A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
WO2012034079A3 (en) Macrolide dosage forms
NZ599847A (en) Pharmaceutical composition comprising a glp-1 agonist and methionine
UA106634C2 (uk) Тверда фармацевтична дозована форма
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
WO2008146178A3 (en) A novel tablet dosage form
AU2008347158A8 (en) Oral pharmaceutical dosage forms
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
WO2008116195A3 (en) Compositions comprising an sglt2 ingibitor for treating obesity
WO2012054831A3 (en) Ready to use ketorolac formulations
MX2010007083A (es) Combinacion anti-retroviral.
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
MX2011011829A (es) Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico.
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
AR061047A1 (es) Comprimido bicapa para la prevencion de los accidentes cardiovasculares, su uso, y metodo para la prevencion de accidentes cardiovasculares
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
MY152951A (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2011061516A3 (en) Topical foam composition
IN2014DN01619A (es)
WO2011064558A3 (en) Pharmaceutical composition
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal